 TEMPLE CITY, Calif.--BUSINESS WIRE--Fulgent Genetics, Inc. NASDAQ: FLGT Fulgent Genetics or the company, a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Wednesday February 23, 2022. The companys Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer 